| Non-Hodgkin Lymphoma by Clinical Course studied in …STUDIED_INderived200 of 1,200show all (up to 200) |
|---|
| → studied in | NCT03278782Phase 1/Phase 2 · active not recruiting Study of Pembrolizumab (MK-3475) in Combination With Romidepsin · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04074746Phase 1/Phase 2 · completed Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07231952Phase 2 · recruiting A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00923507recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01676805recruiting Tissue Collection for Studies of Lymph Cancer · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06454149recruiting Cohort Study for Gastric MALT Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05783596Phase 2 · active not recruiting Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561048Phase 3 · recruiting Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04414163Phase 2 · active not recruiting A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04728893Phase 2 · recruiting Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) · condition mapped PROBABILISTIC · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840602Phase 2 · recruiting Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Lymphoplasmacytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07548450Phase 2 · not yet recruiting Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04301076Phase 1 · recruiting Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Acute Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00039676active not recruiting Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05296070Phase 2 · recruiting Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05944562Phase 1 · active not recruiting Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06647732Phase 2 · active not recruiting Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02180724Phase 2 · active not recruiting An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06137144Phase 1/Phase 2 · recruiting AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06724237Phase 3 · recruiting Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003100recruiting A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07168486Phase 1 · enrolling by invitation CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819396Phase 2 · not yet recruiting Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01318317Phase 1/Phase 2 · active not recruiting Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04542824Phase 1/Phase 2 · active not recruiting Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326308recruiting Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07387471Phase 2 · active not recruiting Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03380026Phase 2 · completed Mechlorethamine Induced Contact Dermatitis Avoidance Study · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680052Phase 3 · active not recruiting A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393738Phase 1 · recruiting A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624906Phase 2 · active not recruiting Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04803201Phase 2 · recruiting Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04930653Phase 2 · recruiting Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Folliculotropic Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01961063Phase 1 · active not recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | AIDS-Related Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04315324Phase 1/Phase 2 · active not recruiting Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561347Phase 2 · recruiting Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07432022Phase 1/Phase 2 · recruiting A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791498Phase 2 · not yet recruiting Teclistamab In Waldenstrom's Macroglobulinemia · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791615Phase 2 · not yet recruiting A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma · condition mapped PROBABILISTIC · 1,200 trials mapped (405 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03521596completed Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04904146recruiting Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166419Phase 1 · active not recruiting Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07388563Phase 1 · suspended Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07781449Phase 2 · not yet recruiting Topical JAK-Inhibition of Early-Stage CTCL · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959085Phase 3 · recruiting Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389423Phase 1 · recruiting Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441214active not recruiting Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07055477Phase 1 · recruiting A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03884998Phase 1 · active not recruiting Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404088Phase 2 · active not recruiting Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792502Phase 2 · recruiting Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05254899Phase 2 · completed A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07777120active not recruiting Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00336063Phase 1 · active not recruiting Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02223208Phase 1/Phase 2 · completed Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02702310suspended Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710418NA · recruiting Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06927466Phase 1 · recruiting A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735533Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768943Phase 2 · not yet recruiting GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662928Phase 2 · not yet recruiting Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07766421Phase 3 · not yet recruiting Evaluation of Iopofosine I 131 vs. R-CD in WM Patients · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03409432Phase 2 · completed Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Primary Cutaneous Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06980116Phase 1 · recruiting Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649304Phase 1 · not yet recruiting AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | AIDS-Related Diffuse Large B-cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07678229Phase 3 · recruiting BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07727083recruiting Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07759661not yet recruiting Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06340737Phase 1 · recruiting AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Lymphoplasmacytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792825Phase 2 · recruiting HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07758673Phase 1 · not yet recruiting Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03136146Phase 2 · recruiting Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Adult Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07169331Phase 4 · active not recruiting A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03504644Phase 1/Phase 2 · active not recruiting Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Adult Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05640102recruiting Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656835NA · active not recruiting Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990465Phase 1 · recruiting LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06600568recruiting Novel Therapeutic Approach for Human T-cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07744750Phase 2 · not yet recruiting Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750886recruiting Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01804686Phase 3 · recruiting A Long-term Extension Study of PCI-32765 (Ibrutinib) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02443077Phase 3 · active not recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03011814Phase 1/Phase 2 · recruiting Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Folliculotropic Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06708897Phase 1 · recruiting A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069699Phase 1/Phase 2 · recruiting Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02981628Phase 2 · active not recruiting Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914625Phase 3 · active not recruiting A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07072585Phase 2/Phase 3 · not yet recruiting Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07424833Phase 1 · recruiting A Study of APG-3288 in Relapsed/Refractory Blood Cancers · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609862Phase 1/Phase 2 · recruiting A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03264131Phase 2 · completed BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05357794Phase 2 · recruiting Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07459608Phase 2 · not yet recruiting Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04333524active not recruiting FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07121946Phase 1 · recruiting This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04212013Phase 3 · active not recruiting A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717580Phase 2 · not yet recruiting Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05735834Phase 3 · active not recruiting Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04703192Phase 2 · active not recruiting Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06471738Phase 2 · recruiting Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07713459Phase 2 · not yet recruiting A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714187Phase 1 · not yet recruiting A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05024045Phase 1 · completed Study of Oral LOXO-338 in Patients With Advanced Blood Cancers · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711327not yet recruiting Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01352520Phase 2 · active not recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Primary Cutaneous Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06207812recruiting Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00501826Phase 2 · recruiting Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371630Phase 1/Phase 2 · recruiting Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Large B-Cell Lymphoma with 11q Aberration | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02494700Phase 2 · active not recruiting Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705308Phase 2 · not yet recruiting A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05828589Phase 1 · terminated A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580002Phase 2 · recruiting Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043011recruiting Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06470451Phase 3 · terminated Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | AIDS-Related Diffuse Large B-cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05303792Phase 2 · active not recruiting Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665062Phase 1 · active not recruiting Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Indolent B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06300528Phase 2 · active not recruiting Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691450Phase 1 · not yet recruiting Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Enteropathy-Associated T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03810196NA · recruiting CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07420959Phase 1/Phase 2 · not yet recruiting ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04416451Phase 2 · active not recruiting A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05805605Phase 2 · recruiting Allo HSCT Using RIC and PTCy for Hematological Diseases · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05131022Phase 1 · recruiting A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02339922Phase 2 · active not recruiting Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Lymphoplasmacytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04256018Phase 2 · recruiting Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06508463Phase 1 · recruiting Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06860880NA · recruiting Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07678307Phase 1/Phase 2 · not yet recruiting A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653271Phase 1 · completed ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06905509Phase 2 · recruiting Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01209871Phase 1 · completed Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Lymphoplasmacytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520791Phase 1 · active not recruiting Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314974Phase 2 · recruiting Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07664787NA · not yet recruiting Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Grade 1 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00408005Phase 3 · completed Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03277729Phase 1/Phase 2 · active not recruiting A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 1,200 trials mapped (405 active) | — | — | Lymphoplasmacytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545762Phase 1 · recruiting Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05700149recruiting Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07376330not yet recruiting Molecular and Cellular Characterization of MALT Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07592481NA · not yet recruiting Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07658924Phase 2 · not yet recruiting Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502768Phase 1/Phase 2 · recruiting Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07657494NA · recruiting Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study · condition mapped ALIAS · 1,200 trials mapped (405 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05475925Phase 1/Phase 2 · recruiting A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Primary Cutaneous Gamma-Delta T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06636175early Phase 1 · recruiting 64Cu-LLP2A for Imaging Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07654465Phase 2 · not yet recruiting Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01787409NA · active not recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05414500Phase 1 · suspended Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06006117Phase 3 · recruiting Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02232516Phase 2 · completed Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,200 trials mapped (405 active) | — | — | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |